吉西他滨联合奥沙利铂治疗复发或转移胸腺癌近期临床疗效观察-现代医学

吉西他滨联合奥沙利铂治疗复发或转移胸腺癌近期临床疗效观察

作者：王俊杰

单位：河南省新乡市中心医院

分类号：

出版年·卷·期（页码）：2014··第一期（0-）

摘要：

【摘要】背景与目的：晚期复发转移性胃癌患者临床治疗效果较差，探索新的二线治疗方案是目前研究的热点。方法: 观察38例晚期复发转移胃癌二线治疗患者，给予吉西他滨联合阿霉素化疗，每例至少完成2周期以上化疗（2-8周期），共132周期化疗。结果： 38例患者均可评价，临床有效率39.4%，疾病控制率 63.2%。中位生存期（从接受本化疗方案计算）11.5个月（4-31个月），1年生存率35.7%。结论：吉西他滨联合阿霉素对于晚期复发转移胃癌患者有较好的临床有效率及疾病控制率，不良反应可以耐受，值得进一步临床研究。

【Abstract】Background and purpose ：The survival of advanced gastric cancer Is poor, explore new second-line chemotherapy regimens is needed. Mehtods : 38 cases of the patients were treated weith Gemcitabine (1000 mg/m2) was given as a 30 min, infusion, adriamycin (50mg/m2),injection. The regimen was repeated every 3 weeks. Treatment efﬁcacy was evaluated every 2 cycles. Results: Patients received a total of 132 cycles of treatment, and all were evaluable for efﬁ cacy and toxicity. The response rate (RR) was 39.4%. The disease control rate (DCR) was 63.2%. The median survival time was 11.5 months. The survival rate was 35.7% in the first year. Conclusion：Gemcitabine combined with adriamycin regimen is effective in the treatment of advanced gastric cancer as second line treatment. The side-effects are mild.

参考文献：

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录